TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in the Journal of Clinical Investigation links pulmonary hypertension with brain changes in regions involved in memory, attention and planning. Researchers also connected those changes to inflammation and the NCOA7 gene, but the findings do not establish a screening test or treatment.
Researchers from the University of Pittsburgh and UPMC have linked pulmonary hypertension to brain tissue loss, altered communication between brain regions and inflammation, offering a possible biological explanation for patients’ reports of memory and concentration problems. The study, published November 2 in the Journal of Clinical Investigation, also connects the brain changes to the NCOA7 gene, though it does not establish a clinical screening test or treatment.
The team compared brain MRI scans from people with pulmonary hypertension with scans from people without the disease, drawing on a large public health database and a smaller group of UPMC patients. Both groups of patients with pulmonary hypertension showed a consistent loss of brain tissue and weaker communication between the cerebellum and frontal lobe. These regions have roles in memory, attention and planning, the report said.
The researchers said the pattern was not seen in people with other heart, lung or psychiatric conditions in their comparisons. They also reported that the differences could not be explained by low blood oxygen, impaired heart function or medications used to treat pulmonary hypertension. The findings suggest the brain changes may be associated with the disease process itself, rather than simply reflecting those factors.
Genetic analyses and laboratory work linked a variant in NCOA7, previously associated with inflammatory responses in pulmonary hypertension, to inflammation in the cerebellum. In tissue from patients and mice, the team observed signs of overactive microglia, the brain’s immune cells, and changes in neurons. Mice with pulmonary hypertension that also lacked NCOA7 had more severe cerebellar damage than mice with the disease alone. That result supports a role for the gene in regulating brain inflammation in the mouse model; it does not by itself show how the gene acts in every patient.
Brain Effects May Be Part of the Disease
Pulmonary hypertension is high blood pressure in the blood vessels of the lungs. It can cause shortness of breath, chest pain and lightheadedness, and the study suggests that its effects may extend beyond the heart and lungs to cognitive function. Memory and concentration difficulties could affect daily life and quality of life, but patients may not connect those symptoms to their vascular condition.
The findings may also matter for clinical care: the report says current pulmonary hypertension management guidelines do not include cognitive screening, and there is no biological marker in routine use to predict or track the disease’s effects on the brain. The study identifies a possible marker and inflammation as a potential research target, not a ready-to-use test or proven therapy. Researchers will need further work to establish whether either could guide care.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Levoit EverestAir-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
From Lung Inflammation to Brain Findings
Stephen Chan, a University of Pittsburgh and UPMC researcher-clinician, began investigating NCOA7 after earlier research identified a variant in the gene associated with inflammatory responses in pulmonary hypertension. According to the supplied report, the variant is present in about one-quarter of patients and is associated with worse survival odds. Chan hypothesized that the same biology might be linked to inflammation in the brain.
The new study, led by Okawa and colleagues, combined brain imaging, genetic analysis and laboratory studies. Its title is “Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis.” The results build on the researchers’ prior work, but the reported patient comparisons and mouse experiments answer different questions: human data show associations, while the mouse findings provide evidence about a possible causal role for NCOA7 in that model.
“Patients often assume memory issues or trouble concentrating are unrelated to their pulmonary hypertension. Our findings suggest those symptoms are a central part of the disease process and deserve attention.”
— Stephen Chan
Clinical Screening Still Unproven
The report does not establish how common cognitive impairment is among all people with pulmonary hypertension, nor whether the MRI changes predict future decline in an individual patient. It also does not give a validated threshold for using NCOA7 as a screening or monitoring marker. The supplied material does not detail the size or demographic makeup of each patient group, limiting assessment of how broadly the results apply.
The human findings link disease, brain changes and inflammation, but they do not prove that NCOA7 causes cognitive symptoms in people. The mouse experiments add evidence of a causal role in that model, while further studies are needed to clarify the mechanism in humans. Chan’s suggestion that similar processes may matter in dementia, aging or other inflammatory conditions remains speculative based on this report.
Validation Before Changes to Care
The immediate next step is independent and larger-scale research to test whether the brain imaging pattern and NCOA7-related measures can be reproduced across patient populations. Studies would also need to determine whether these measures track cognitive changes over time and whether screening can identify people who benefit from further assessment.
The paper points to inflammation as a potential therapeutic target, but it does not report a treatment trial or show that reducing inflammation preserves cognition. Until clinical evidence is available and care guidance changes, the findings should be treated as an explanation under investigation rather than a new diagnostic or treatment recommendation. The study was published in the Journal of Clinical Investigation under DOI 10.1172/jci195110.
Key Questions
What did the study find about pulmonary hypertension and the brain?
It reported brain tissue loss and weaker communication between the cerebellum and frontal lobe in people with pulmonary hypertension, alongside evidence linking the changes to inflammation.
Does the research prove pulmonary hypertension causes memory problems?
No. The human findings show an association between the disease and brain changes. Laboratory and mouse results support a possible mechanism, but the study does not prove that the same mechanism causes cognitive symptoms in every patient.
Can NCOA7 be used to screen patients now?
Not on the evidence reported. NCOA7 is a potential biological marker, but it has not been established as a validated clinical screening or monitoring test.
Do the findings change pulmonary hypertension treatment?
The report describes no treatment trial or change to clinical guidelines. It identifies inflammation as a possible research target; further studies are needed before the findings can guide treatment.
Source: news-medical.net
![I Made Tinnitus My Friend, Then It Disappeared [Video]](https://breatheatlas.com/wp-content/uploads/2026/08/i-made-tinnitus-my-friend-then-it-disappeared-video-featured-560x300.jpg)
